CA2397169A1 - Ligands cibles - Google Patents

Ligands cibles Download PDF

Info

Publication number
CA2397169A1
CA2397169A1 CA 2397169 CA2397169A CA2397169A1 CA 2397169 A1 CA2397169 A1 CA 2397169A1 CA 2397169 CA2397169 CA 2397169 CA 2397169 A CA2397169 A CA 2397169A CA 2397169 A1 CA2397169 A1 CA 2397169A1
Authority
CA
Canada
Prior art keywords
ligand
moiety
target
composition according
affinity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2397169
Other languages
English (en)
Inventor
William Herman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA 2397169 priority Critical patent/CA2397169A1/fr
Priority to US10/501,453 priority patent/US20050069549A1/en
Priority to EP09003542A priority patent/EP2075256A2/fr
Priority to CA002513287A priority patent/CA2513287A1/fr
Priority to EP03700256A priority patent/EP1497331A2/fr
Priority to PCT/CA2003/000044 priority patent/WO2003057732A2/fr
Priority to AU2003201559A priority patent/AU2003201559A1/en
Publication of CA2397169A1 publication Critical patent/CA2397169A1/fr
Priority to US10/943,918 priority patent/US20050142539A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA 2397169 2002-01-14 2002-08-13 Ligands cibles Abandoned CA2397169A1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CA 2397169 CA2397169A1 (fr) 2002-08-13 2002-08-13 Ligands cibles
US10/501,453 US20050069549A1 (en) 2002-01-14 2003-01-14 Targeted ligands
EP09003542A EP2075256A2 (fr) 2002-01-14 2003-01-14 Ligands ciblés
CA002513287A CA2513287A1 (fr) 2002-01-14 2003-01-14 Ligands cibles
EP03700256A EP1497331A2 (fr) 2002-01-14 2003-01-14 Ligands cibles
PCT/CA2003/000044 WO2003057732A2 (fr) 2002-01-14 2003-01-14 Ligands cibles
AU2003201559A AU2003201559A1 (en) 2002-01-14 2003-01-14 Multispecific binding molecules
US10/943,918 US20050142539A1 (en) 2002-01-14 2004-09-20 Targeted ligands

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA 2397169 CA2397169A1 (fr) 2002-08-13 2002-08-13 Ligands cibles

Publications (1)

Publication Number Publication Date
CA2397169A1 true CA2397169A1 (fr) 2004-02-13

Family

ID=31501584

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2397169 Abandoned CA2397169A1 (fr) 2002-01-14 2002-08-13 Ligands cibles

Country Status (1)

Country Link
CA (1) CA2397169A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10071158B2 (en) 2005-04-26 2018-09-11 Lindis Biotech Gmbh Combination of the application of antibodies for immunostimulation together with glucocorticoids

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10071158B2 (en) 2005-04-26 2018-09-11 Lindis Biotech Gmbh Combination of the application of antibodies for immunostimulation together with glucocorticoids
US10576149B2 (en) 2005-04-26 2020-03-03 Lindis Biotech Gmbh Combination of the application of antibodies for immunostimulation together with glucocorticoids

Similar Documents

Publication Publication Date Title
US20090104195A1 (en) Targeted ligands
US20050069549A1 (en) Targeted ligands
US11091546B2 (en) Optimized PNE-based chimeric receptor T cell switches and uses thereof
JP6929951B2 (ja) 抗ｌａｇ−３抗体およびその使用
US20050142539A1 (en) Targeted ligands
KR101017732B1 (ko) 내재화 항-ｃｄ74 항체 및 그 이용방법
JP6389166B2 (ja) 抗ｂ７−ｈ６抗体、融合タンパク質、及びこれらを使用する方法
TWI676681B (zh) 具抗原專一性的t細胞及其用途
CA2927543A1 (fr) Commutateurs de cellules t a recepteur d'antigene chimere peptidique et leurs utilisations
TW200846370A (en) Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR)
TR201809743T4 (tr) Kan beyin bariyerinden terapötik moleküllerin taşınmasının arttırılması.
JP2019523651A (ja) 抗ｐｓｍａ抗体およびその使用
US20240002526A1 (en) Uses of effector cell engaging molecules with moieties of differing potencies
KR20180098672A (ko) 자가-가교결합 항체
US20220323600A1 (en) Teac and attac immunooncology compositions and methods
JP2020072686A (ja) 二重特異性抗原結合ポリペプチド
US9200078B2 (en) Antibodies against prostate-specific stem cell antigen and use thereof
US20240002524A1 (en) Methods and compositions
JP2020533970A (ja) 抗ｃｄ３抗体とその作製及び使用方法
CA2414148A1 (fr) Ligands cibles
KR20220024035A (ko) Muc16 및 cd3에 결합하는 이중 특이적 항원 결합 분자와 4-1bb 공동 자극의 병용
CA2397169A1 (fr) Ligands cibles
CA2402930A1 (fr) Ligands cibles
CA2513287A1 (fr) Ligands cibles
JP2022541504A (ja) がん治療のためのインテグリン標的化ノッティン－ｆｃ融合体と抗ｃｄ４７抗体の併用

Legal Events

Date Code Title Description
FZDE Dead